Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma

PURPOSE: Mavorixafor is an oral, selective inhibitor of the CXCR4 chemokine receptor that modulates immune cell trafficking. A biomarker-driven phase Ib study (NCT02823405) was conducted in 16 patients with melanoma to investigate the hypothesis that mavorixafor favorably modulates immune cell profi...

ver descrição completa

Detalhes bibliográficos
Principais autores: Andtbacka, Robert H.I., Wang, Yan, Pierce, Robert H., Campbell, Jean S., Yushak, Melinda, Milhem, Mohammed, Ross, Merrick, Niland, Katie, Arbeit, Robert D., Parasuraman, Sudha, Bickley, Kris, Yeung, Cecilia CS, Aicher, Lauri D., Smythe, Kimberly S., Gan, Lu
Formato: Online Atigo Texto
Idioma:English
Publicado em: American Association for Cancer Research 2022
Assuntos:
Research Article
Acesso em linha:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010370/
https://www.ncbi.nlm.nih.gov/pubmed/36923305
http://dx.doi.org/10.1158/2767-9764.CRC-22-0090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010370/
https://www.ncbi.nlm.nih.gov/pubmed/36923305
http://dx.doi.org/10.1158/2767-9764.CRC-22-0090

Registros relacionados